key: cord-0801376-vqr9xt2e
authors: Ricardo, Jose W.; Chikeka, Ijeuru; Silvers, David N.; Lipner, Shari R.
title: Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy
date: 2020-11-06
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2020.10.030
sha: 77e702d0238a6ac8d7bde7a0f43136f5be99b732
doc_id: 801376
cord_uid: vqr9xt2e

nan

Antimalarials, including hydroxychloroquine (HCQ), may cause hyperpigmentation of the skin, mucous membrane, joints, and cartilage. [1] [2] [3] Longitudinal melanonychia, a linear brown-black nail plate band, is rarely reported with HCQ treatment, and histologic confirmation has not been previously published. HCQ is widely used for the treatment of various rheumatic and dermatologic diseases, including systemic lupus erythematosus, cutaneous lupus, and rheumatoid arthritis. It inhibits the replication of SARS-CoV-2 in vitro 4 and has been used to treat COVID-19. Herein, we present a case of skin hyperpigmentation and longitudinal melanonychia with a histology associated with HCQ therapy.

A 66-year-old woman, Fitzpatrick skin type II, with mixed connective tissue disease presented with a 7-year history of a pigmented band on her left thumbnail. She was treated with HCQ for 18 years, which was discontinued 4 years before the consultation because of progressive skin hyperpigmentation of the lower portion of the legs. At the time of the skin hyperpigmentation (3 years after HCQ initiation) and melanonychia (15 years after HCQ initiation) presentations, the cumulative dosages of HCQ were 438 g and 2190 g, respectively. Prior biopsy of the skin from the lower portion of the legs with histopathology showed dermal intracellular and extracellular yellow-to-brown granules positive for Fontana-Masson and Perl's stains. The medications at the time of the consultation included clopidogrel due to transient ischemic attacks, prednisone, bupropion, diltiazem, gabapentin, and levothyroxine. Physical examination was significant for hyperpigmented macules and patches involving the lower portion of the legs and a longitudinal graybrown band of the left thumbnail (Fig 1, A) . Nail dermoscopic evaluation revealed a gray-brown background with regular gray-brown lines (Fig 1,  B) . A tangential shave biopsy of the nail matrix and histopathology with hematoxylin-eosin staining showed brown nonrefractile and coarsely granular pigment deposition in the superficial dermis of the nail matrix (Fig 2, A) . The pigment was extracellular and within macrophages and fibroblasts. The Fontana-Masson staining highlighted these granules, confirming the presence of melanin (Fig 2, B) . The Perl's iron staining result was negative for hemosiderin. The histologic differential diagnosis included melanin incontinence secondary to postinflammatory pigmentary alteration and HCQ-induced hyperpigmentation. Due to these nail histologic findings and prior pathology confirming HCQ-induced skin hyperpigmentation, along with a high cumulative HCQ dose, a diagnosis of HCQ-induced hyperpigmentation was favored. Other causes of druginduced melanonychia were excluded.

After drug rash/eruption (52%), gray/blue skin hyperpigmentation (17%) is the most common dermatologic manifestation of HCQ treatment. 3 Since there is an increased iron concentration in hyperpigmented skin, 1 it has been hypothesized that trauma and bruising with increased levels of hemosiderin activate melanocytes. 5 In a retrospective case-control study including 24 and 517 HCQtreated systemic lupus erythematosus patients with and without HCQ-induced skin hyperpigmentation, respectively, 96% (23/24) of the patients with hyperpigmentation had a predisposition to bruising, including the use of platelet antiaggregants and/or oral anticoagulants. 5 Although there is no significant dose-dependent relationship, 5 HCQ-induced melanonychia and skin hyperpigmentation have been reported with cumulative dosages of $ 230 g and $ 452 g, respectively. 3 The histopathologic findings of HCQ-induced hyperpigmentation are yellow-tobrown granules within macrophages and fibroblasts and extracellularly in the dermis. 2, 5 The granules stain positive for either melanin 2 or both melanin and hemosiderin, 5 typically demonstrating hemosiderin around capillaries and melanin in the deeper layers of the dermis. 2 In the present case, the histologic evaluation revealed the presence of melanin and absence of Fig 1. A, Left thumbnail with a central longitudinal gray-to-brown band originating in the distal matrix, 1 mm proximally and 2 mm distally, with a distal superficial split over the pigmented area. There was no pigment involving the nail folds or hyponychium. B, Dermoscopic appearance showing a gray-to-brown background with gray-to-brown lines of regular color, spacing, and thickness, without loss of parallelism. hemosiderin. Although drug-induced melanonychia typically involves several nails, 6 HCQ was likely causative of skin/nail hyperpigmentation for a number of reasons. Skin hyperpigmentation and melanonychia occurred 3 (cumulative dosage = 438 g) and 15 years (cumulative dosage = 2190 g) after the HCQ initiation, respectively, with skin pigmentation worsening during the treatment. The patient reported that her leg hyperpigmentation followed bruising, with the histologic evaluation confirming the presence of melanin and hemosiderin. She also took clopidogrel and systemic corticosteroids, both of which can facilitate bruising. Finally, the grayish color of her skin and nail was consistent with HCQ hyperpigmentation. 3 The most important differential diagnosis of longitudinal melanonychia is nail-unit melanoma, a life-threatening but potentially treatable form of cancer if diagnosed and managed at early stages. A nail biopsy is often necessary to differentiate between drug-induced melanonychia and subungual melanoma with the involvement of a single nail unit. HCQ-induced skin/nail hyperpigmentation may fade after drug discontinuation but may not disappear completely. 2, 5 To the best of our knowledge, this is the first histopathologically confirmed case of melanonychia and skin hyperpigmentation associated with HCQ therapy.

Pigmentation from antimalarial therapy: its possible relationship to the ocular lesions

Hydroxychloroquine-induced hyperpigmentation: the staining pattern

Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study

Drug-induced nail diseases